Biofrontera (BFRI) Cost of Revenue (2020 - 2025)

Biofrontera's Cost of Revenue history runs 6 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• On a quarterly basis, Cost of Revenue fell 42.91% year-over-year to $3.0 million in Q4 2025; TTM through Dec 2025 was $11.0 million, a 41.07% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, down 41.08% from the prior year.
• Cost of Revenue grew to $3.0 million in Q4 2025 per BFRI's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $17.5 million in Q4 2022 and bottomed at -$1.4 million in Q4 2023.
• The 5-year median for Cost of Revenue is $2.3 million (2025), against an average of $2.7 million.
• Across the five-year window, Cost of Revenue jumped 9554.7% in 2022 and plunged 107.76% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $181000.0 in 2021, then soared by 9554.7% to $17.5 million in 2022, then plunged by 107.76% to -$1.4 million in 2023, then surged by 488.72% to $5.3 million in 2024, then slumped by 42.91% to $3.0 million in 2025.
• Per Business Quant, the three latest BFRI Cost of Revenue figures stand at $3.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.6 million (Q2 2025).